Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.By TCTMD

Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.By TCTMD

Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.By TCTMD

Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.By TCTMD

Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.By TCTMD

Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.By TCTMD

Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.By TCTMD

Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.By TCTMD

Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.By TCTMD

A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.By TCTMD

Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.By TCTMD

Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.By TCTMD

Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.By TCTMD

Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.By TCTMD

Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.By TCTMD

Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).By TCTMD

Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.By TCTMD

Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.By TCTMD

Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.By TCTMD

Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillationBy TCTMD

Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.By TCTMD

Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.By TCTMD

Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.By TCTMD

Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.By TCTMD

Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.By TCTMD

Milind Desai and C. Michael Gibson compare the results of mavacamten for severe obstructive hypertropic cardiomyopathy with the typical treatments of surgical septal myectomy or alcohol ablation.By TCTMD

Justin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.By TCTMD

Shamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.By TCTMD

Tijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.By TCTMD

Mark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.By TCTMD

Gregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.By TCTMD

Javed Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.By TCTMD

Florian Rader and C. Michael Gibson look at cumulative outcomes for patients with obstructive hypertrophic cardiomyopathy treated with mavacamten.By TCTMD

Manesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in patients with atrial fibrillation.By TCTMD

Daniel Sessler and C. Michael Gibson compare myocardial injury rates following mild hypothermia versus aggressive warming during noncardiac surgery.By TCTMD

Duk-Woo Park and C. Michael Gibson discuss edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after TAVI.By TCTMD

Bon-Kwon Koo and C. Michael Gibson compare the efficacy of FFR-guided and IV ultrasound-guided PCI for coronary artery stenosis.By TCTMD

Marie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.By TCTMD

Felix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.By TCTMD

Paul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.By TCTMD

Michael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.By TCTMD

C. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.By TCTMD

C. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.By TCTMD

Episode 162: The FIGARO-DKD Trial by TCTMDBy TCTMD

C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.By TCTMD

C. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.By TCTMD

C. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.By TCTMD

C. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.By TCTMD

C. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.By TCTMD

C. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.By TCTMD